Sotradecol (sodium tetradecyl sulfate)
Venosclerosing Agents Intravenous Vial (ML)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Sodium tetradecyl sulfate (STS), an anionic surfactant and detergent, is used as a sclerosing agent.
Sodium tetradecyl sulfate (STS) is an anionic surfactant and detergent used as a sclerosing agent. The drug is commercially available in the US as a sterile, nonpyrogenic 1 or 3% solution. Each mL contains 10 mg (1%) or 30 mg (3%) of sodium tetradecyl sulfate with benzyl alcohol (0.02 mL) and dibasic sodium phosphate anhydrous in water for injection.
The solution has a pH of 7.9; monobasic sodium phosphate and/or sodium hydroxide are added for pH adjustment.
Following IV injection, sodium tetradecyl sulfate causes inflammation of the intima and thrombus formation, which usually occludes the target vein. Subsequent formation of fibrous tissue results in partial or complete vein obliteration; the effect on the vein may or may not be permanent.
Generic name: sodium tetradecyl sulfate
Drug class: Venosclerosing Agents
Therapeutic class: Cardiovascular Therapy Agents
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Sotradecol
Indications
The following indications are listed for Sotradecol:
- Varicose Veins
Dosing
No dosing information is available for this tab.
Sodium tetradecyl sulfate is administered only by IV injection. Extravasation should be avoided. (See Administration Precautions under Cautions: Warnings/Precautions.)
Sodium tetradecyl sulfate is commercially available as a 1 or 3% solution in vials (containing a total of 20 or 60 mg, respectively, in each 2-mL vial). Although the drug has been administered as an endovenous foam or microfoam, these preparations are not commercially available in the US and extemporaneous preparation of sodium tetradecyl sulfate foam is not approved by the US Food and Drug Administration (FDA).
Unopened vials of sodium tetradecyl sulfate solution should be stored at 20-25degreesC.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Sodium tetradecyl sulfate solutions that have precipitated or are discolored should not be used.
Sodium tetradecyl sulfate is incompatible with heparin; therefore, the 2 drugs should not be mixed in the same syringe.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
Sodium Tetradecyl Sulfate/Estrogens
SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.
MECHANISM OF ACTION: Patients taking estrogen-containing hormonal contraceptives or hormone replacement therapy have a higher risk of clotting problems.(1)
CLINICAL EFFECTS: Use of sodium tetradecyl sulfate on patients taking estrogen-containing hormonal contraceptives or hormone replacement therapy may increase the risk of deep vein thrombosis.(1)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: The manufacturer of sodium tetradecyl sulfate states that its use in patients taking contraceptives or hormone replacement therapy is contraindicated.(2)
DISCUSSION: Factors which may increase the risk of deep vein thrombosis after sclerotherapy should be avoided.(1) Therefore, its use in patients taking estrogen-containing contraceptives or hormone replacement therapy is contraindicated.(2)
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
Sodium tetradecyl sulfate is contraindicated in patients with a history of hypersensitivity reactions to the drug or history of allergic conditions. (See Sensitivity Reactions under Cautions: Warnings/Precautions.)
Sodium tetradecyl sulfate is contraindicated in patients with acute superficial thrombophlebitis, valvular or deep vein incompetence, huge superficial veins with wide open communications to deeper veins, phlebitis migrans, or varicosities caused by abdominal and pelvic tumors (unless the tumor has been removed).
The drug also is contraindicated in bedridden patients or patients with acute cellulitis, acute infections, or uncontrolled systemic diseases (e.g., diabetes, toxic hyperthyroidism, tuberculosis, asthma, neoplasm, sepsis, blood dyscrasias, acute respiratory disease, skin disease).
- Active tuberculosis
- Asthma exacerbation
- Bed-ridden
- Blood dyscrasias
- Peripheral venous insufficiency
- Sepsis
- Thrombophlebitis
- Thrombophlebitis migrans
- Thyrotoxicosis
- Uncontrolled diabetes mellitus
There are no severe contraindications for this drug.
- Buerger's disease
- Severe arteriosclerotic vascular disease
Adverse reactions
Adverse effects reported in patients treated with sodium tetradecyl sulfate include injection site reactions (pain, urticaria, ulceration), discoloration along the path of a sclerosed vein segment (may be permanent), allergic reactions, and mild systemic reactions (headache, nausea, vomiting).
Less Frequent
- Tissue necrosis
Rare or Very Rare
- Anaphylaxis
- Asthma
- Deep venous thrombosis
- Pulmonary thromboembolism
Less Frequent
- Dyschromia
- Headache disorder
- Injection site sequelae
- Nausea
- Urticaria
- Vomiting
Rare or Very Rare
- Allergic rhinitis
Precautions
No enhanced messaging available.
Safety and efficacy of sodium tetradecyl sulfate have not been established in pediatric patients.
Category C. (See Users Guide)
There are no adequate and well-controlled studies using sodium tetradecyl sulfate in pregnant women; the drug should be used during pregnancy only if clearly needed and if the benefits outweigh the risks.
It is not known whether sodium tetradecyl sulfate is distributed into human milk. Because many drugs are distributed into milk, sodium tetradecyl sulfate should be used with caution in nursing woman.
No enhanced messaging available.
ICD codes
| Code | Type | Description |
|---|---|---|
| Varicose veins | ||
| I83.9 | ICD10CM | Asymptomatic varicose veins of lower extremities |
| I83.90 | ICD10CM | Asymptomatic varicose veins of unspecified lower extremity |
| I83.91 | ICD10CM | Asymptomatic varicose veins of right lower extremity |
| I83.92 | ICD10CM | Asymptomatic varicose veins of left lower extremity |
| I83.93 | ICD10CM | Asymptomatic varicose veins of bilateral lower extremities |
| O22.00 | ICD10CM | Varicose veins of lower extremity in pregnancy, unspecified trimester |
| O22.01 | ICD10CM | Varicose veins of lower extremity in pregnancy, first trimester |
| O22.02 | ICD10CM | Varicose veins of lower extremity in pregnancy, second trimester |
| O22.03 | ICD10CM | Varicose veins of lower extremity in pregnancy, third trimester |
| O87.4 | ICD10CM | Varicose veins of lower extremity in the puerperium |
ICD code information from First Databank (FDB).
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.